Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms;  Pancreatic Adenocarcinoma


Zhao Sun


Annals of Oncology (2019) 30 (suppl_5): v194-v197. 10.1093/annonc/mdz245


Z. Sun1, H. Gao1, Y. Cheng2, C. Bai3, Y. Chen4

Author affiliations

  • 1 Oncology, Peking Union Medical College Hospital, 100730 - Beijing/CN
  • 2 Peking Union Medical College Hospital, Chinese Academy Of Medical Sciences, Department of Medical Oncology, 100010 - Beijing/CN
  • 3 Cancer, Beijing Union Medical College Hospital (Xiehe Hospital), 100730 - Beijing/CN
  • 4 Gastroenterology, Department of Medical Oncology, 100730 - Beijing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3697


Pancreatic neuroendocrine tumor (pNET) is rare and heterogeneous. New biomarkers are needed for better predicting the prognosis and providing individualized treatment. Versican (VCAN) plays an important role in tumorigenesis. Our previous study showed VCAN was specifically expressed in pNET tumor tissue. Therefore, we planned to investigate the role of VCAN in pNET prognosis.


Clinical and pathological data of pNET patients who underwent surgery between 2005 and 2010 were followed up and evaluated. VCAN expression was assessed by immunohistochemical (IHC) methods, and the relationship between VCAN and prognostic features of pNET was analyzed.


Among 161 pNET patients, 118 (73.3%) pNET were VCAN expression positive and 43 (26.7%) VCAN expression negative. Positive expression of VCAN in pNET was significantly associated with longer disease-free survival (DFS) compared with VCAN-negative pNET (p = 0.017, HR 0.399, 95%CI 0.215-0.741). Subgroup analysis showed that VCAN-positive expression was associated with longer DFS in the G1 subgroup (p = 0.030, HR = 0.122, 95%CI: 0.013-1.180), tumor size>2cm subgroup (p = 0.030, HR = 0.427, 95%CI: 0.193-0.944) and NF-pNET subgroup (p = 0.001, HR = 0.251, 95%CI: 0.103-0.617). Multiple analysis showed that VCAN-negative expression, G2 and tumor size>2cm were independent factors for poor prognosis in pNET (p = 0.01, p < 0.001, p = 0.009, respectively).


Our data indicate that VCAN-positive expression may serve as an independent factor for predicting DFS prognosis in pNET. VCAN-positive expression in pNET tissues was correlated with longer DFS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


National Natural Science Foundation of China.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.